As a peroxisome proliferator-activated receptor alpha (PPARa) agonist, fenofibrate favorably modulates dyslipidemia and inflammation markers, which are associated with cardiovascular risk. To determine whether variation in the PPARa receptor gene was associated with lipid and inflammatory marker response, we conducted a 3-week trial of fenofibrate in 861 men and women. Mixed linear models that controlled for age and sex, as well as family pedigree and study center, were constructed using single-nucleotide polymorphisms (SNPs) in the PPARa gene as predictors and changes in fasting triglycerides (TGs), cholesterol and inflammatory markers as outcomes. Significant associations with low-density cholesterol and interleukin-2 (Po0.001) responses to fenofibrate were found. Although there were suggestive associations with tumor necrosis factor-alpha and TG responses (Po0.05), these did not survive the correction for multiple testing. We conclude that variants in the PPARa gene may contribute to future pharmacogenomic paradigms seeking to predict fenofibrate responders from both an antidyslipidemic and anti-inflammatory perspective.
INTRODUCTION
Elevated plasma triglyceride (TG), low-density cholesterol lipoprotein (LDL-C) levels and reduced plasma high-density lipoprotein cholesterol (HDL-C) have each been identified as risk factors for cardiovascular disease (CVD). 1, 2 Current evidence suggests that a number of inflammation markers are also potentially useful predictors of prevalent or incident CVD, and interact with dyslipidemia to mediate CVD risk. 3, 4 Drug therapy that reduces plasma TG and LDL-C and raises HDL-C has been shown to lower adverse cardiovascular outcomes. 5, 6 Fenofibrate is an efficacious therapeutic agent for hypertriglyceridemia, reducing plasma TG levels by 35 --50% while having the collateral benefit of raising HDL-C levels by 10 --20%. 7 In addition to their effects on TG and cholesterol, fibrates have been shown to modulate the production of inflammation markers. 8 --12 There is, however, significant interindividual variation in response to fenofibrate. 13 Findings from a number of studies have suggested that lipid, lipoprotein 14 --16 and some inflammation marker 14 --17 responses to drug therapy are partially under genetic influence.
Fibrates are amphipathic carboxylic acids and are agonists of peroxisome proliferator-activated receptor alpha (PPARa). PPARa receptors heterodimerize with the retinoid X receptor and function as transcription factors, regulating the expression of genes. More than 80 genes in humans and mammalian models are known to be regulated by PPARa including apolipoprotein genes (for example, APOA1, APOA2, APOA5 and APOC3), lipoprotein lipase gene, phospholipid transfer protein gene and other genes involved in lipid and lipoprotein metabolism. 18, 19 PPARa is also known to modulate transcriptional pathways involved in inflammation responses. 20 Given that PPARa is the molecular target for fenofibrate and its known, albeit incompletely understood, roles in lipid metabolism and inflammation, we investigated whether genetic variation in the PPARa gene was associated with variation in fasting TG, LDL-C, HDL-C, adiponectin and inflammation marker response to a 3-week fenofibrate trial in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study.
MATERIALS AND METHODS

Subjects and intervention
GOLDN is part of the PROGENI (PROgram for GENetic Interaction) Network, a group of family intervention studies focusing on gene-environment interactions. The participants in the GOLDN study were mainly re-recruited from two National Heart, Lung and Blood Institute Family Heart Study field centers: Minneapolis, MN and Salt Lake City, UT. All subjects were Caucasian and nearly all of European ancestry. Eligibility criteria were (1) X18 years of age; (2) fasting TGs o1500 mg dl À1 ; (3) willing to participate in the study and attend the scheduled clinic exams; (4) member of a family with at least two members in a sibship; (5) aspartate aminotransferase and alanine aminotransferase results within normal range; and (6) creatinine p2.0 mg dl À1 . Exclusion criteria were (1) history of liver, kidney, pancreas, gall bladder disease or malabsorption; (2) current pregnancy; (3) insulin use; (4) use of lipid lower drugs (including prescription, over-the-counter and nutraceuticals; volunteers taking these agents were withdrawn from them at least 4 weeks before the study with physician's approval); (5) use of warfarin; (6) women of childbearing potential not using an acceptable form of contraception; (7) known hypersensitivity to fenofibrate; and (8) history of pancreatitis within 12 months before enrollment. A previous study demonstrated that Caucasians in Utah and Minnesota were homogeneous and pooling data across centers would not threaten the validity of this study. 21 The details of the GOLDN visits are shown in Figure 1 . After granting informed consent, participants underwent a baseline-screening visit. This visit included a fasting blood draw and pregnancy test, if applicable. The day before the first clinical exam, participants came to the clinic for a fasting blood draw. On visits 2 and 4, willing participants underwent a high fat (83% of calories) meal challenge, after an 8-h fast, which required ingesting 700 kcal m À2 of body surface area. 22 Blood draws were collected before the high fat meal (fasting), 3.5 h after ingestion (uptake) and 6 h after ingestion (clearance). The fenofibrate intervention consisted of a 3-week treatment period, in which participants took fenofibrate (160 mg) daily. Lipids were measured twice on the last 2 days of the treatment period after a minimum 8-h fast.
Biochemical analyses
Protocols for measuring TG, HDL-C, LDL-C and fenofibric acid have been previously described. 23, 24 All lipids were measured using the Roche/Hitachi 911 Automatic Analyzer (Roche Diagnostics Corporation, Indianapolis, IN, USA). TGs were measured using a glycerol blanked enzymatic method, cholesterol was measured using a cholesterol esterase, cholesterol oxidase reaction, and LDL-C was measured by a homogeneous direct method (LDL Direct Liquid Select Cholesterol Reagent; Equal Diagnostics, Exton, PA, USA). HDL-C was calculated after precipitation of non-HDL-C with magnesium/dextran. The interlaboratory coefficients of variation in a pooled plasma control were 2.6, 1.9, 3.9 and 1.8% for TGs, cholesterol, HDL-C and LDL-C, respectively.
Inflammatory markers were measured using the following enzymelinked immunosorbent assay kits from R&D Systems (Minneapolis, MN, USA): Quantikine High Sensitivity Human IL-6, Quantikine Human IL-2 sRa, Quantikine Human MCP-1 and QuantiGlo Human TNF-a. The interlaboratory coefficients of variation on a pooled plasma control were 12.3, 5.7, 7.5 and 9.7% for interleukin-6 (IL-6), IL-2, monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-a), respectively.
Single-nucleotide polymorphism selection and genotyping Single-nucleotide polymorphisms (SNPs) were identified through searching public databases such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). We selected 10 SNPs at the PPARa gene on the basis of the following criteria, in order of importance in our selection scheme: (1) validation status, that is, experimentally validated in Caucasians; (2) functional relevance and importance, namely the potential 'functional' SNPs residing within the transcription factor binding sites in the 5 0 promoter region, in the mRNA (messenger RNA) stability regulatory protein binding sites in 3 0 UTR, in exons that change amino-acid sequences or in exon-intron boundaries that alter mRNA splicing; (3) degree of heterozygosity, that is, minor allele frequencies X0.05; and (4) previous evidence of association with lipid measurements. SNP genotyping methods have been described elsewhere. 23 The overall genotyping error and missing rate was B1%. We used the GRR software to detect pedigree errors via graphically inspecting the distribution for marker allele sharing among pairs of family members on all pairs of individuals. SNP allele frequencies were estimated via a maximum-likelihood method. 24 For each SNP, a w 2 -test was used to examine the deviation of SNP genotypes from Hardy --Weinberg equilibrium.
Statistical analyses
Responses to fenofibrate. Lipid and inflammatory responses to fenofibrate were calculated using growth curve models. Eight lipid and inflammatory marker measures were analyzed: TG, LDL-C, HDL-C, adiponectin, IL-2, IL-6, MCP and TNF-a. At time point 1 (fasting), TG, HDL-C, adiponectin, IL-2, IL-6, MCP and TNF-a concentrations were measured. Postprandial lipids were measured at time points 2 (3.5 h post ingestion or uptake) and 3 (6 h post ingestion or clearance). TG concentrations were log transformed to normalize the distribution. The normalized data were used for the growth curve models. Fasting data were used from visits 1 and 2 (pre-fenofibrate) and 3 and 4 (post-fenofibrate; Figure 1 ). For each condition (pre/post), the two draws were treated as repeated measures to reduce error variance in the slope estimation. Growth curve slopes were adjusted for age, age 2 , age 3 , sex and data collection center. Compared with a simple delta phenotype, SOLAR estimated heritabilities were much higher for growth curve phenotypes (450%). In addition to analyzing genotype associations with lipid, lipoprotein and inflammation marker response phenotypes, we analyzed genotype associations with serum fenofibric acid concentrations. For the fenofibric acid phenotype, we used the partial area under the fenofibric acid concentration-time curve (FA AUC 0À6 ) from serum concentrations measured over 6 h (at 0, 3.5 and 6 h after dosing) on the final day of the intervention. To test whether there were significant differences in lipid and inflammatory marker concentrations before and after the fenofibrate trial, t-tests were conducted, stratified by sex, on data that had been transformed where necessary, as above.
SNP-phenotype associations. We used a linear mixed model implemented in SAS (version 9.1, SAS Institute, Cary, NC, USA). The effects of SNP genotypes (categorical variable with three classes) were treated as fixed effects and the dependencies among members within each family were treated as random effects. Field center, age, age 2 , age 3 and gender were included in the model as covariates. To control for multiple testing, false discovery rate (FDR 25 ) procedure was applied to the data, which gives rise to q-values that represent P-values corrected for the number tests run, which seeks to maximize power while correcting for the family-wise error rate in multiple tests. Hardy-Weinberg equilibrium was calculated using Haploview, 26 and all SNPs were in Hardy --Weinberg equilibrium with an a value of P40.05.
The slopes for IL-2, MCP and TNF-a were log transformed to normality for the genetic analysis. The square root was taken of the FA AUC 0À6 values in the genetic models, again, to approximate normality.
Haplotype analysis. For all traits with more than one significant fasting SNP-phenotype association within a haplotype block (Figure 2) we conducted haplotype analysis. Haplotype frequencies were calculated, and included in the association analysis were haplotype frequencies of 40.01. Tests of association, controlling for pedigree were conducted using the haplotype association module hbat within the FBAT program. 
RESULTS
Study sample characteristics
The number of subjects having screened for eligibility was 1327 (639 men and 688 women) from 148 families. Of these, 861 subjects (427 men and 434 women) underwent the fenofibrate intervention, had all genotype data, and had all lipid, lipoprotein and inflammation marker phenotype measures. Table 1 shows the baseline characteristics of this sample. The mean age of men was 50.6 years, and that of women was 51.1 years. Mean phenotype data are shown stratified by sex in Table 1 .
For both men and women, TG and LDL-C concentrations were significantly lower after fenofibrate treatment than those before treatment (all Po0.001). HDL-C increased significantly after fenofibrate treatment (Po0.001). Adiponectin was the only marker which was significantly lower in both men (Po0.0001) and women (P ¼ 0.002); concentrations of IL-2, TNF-a and MCP increased in both men and women (Po0.001) with IL-6 higher in men (P ¼ 0.049) and not in women (P ¼ 0.165).
Single-SNP associations Supplementary Figure 1 shows the location of our SNPs in the PPARa gene and Figure 2 gives a linkage disequilibrium plot from haploview for our 10 SNPs. Table 2 
We additionally conducted SNP-phenotype associations with the post-prandial data at both time points (Figure 1 ). This confirmed our findings with the same significant SNP-lipid associations, in the expected direction (Supplementary Table 1 ). There were no additional significant SNP-trait associations.
Haplotype analysis Only LDL-C and TNF-a were associated with SNPs within a haplotype block (Table 2; Figure 2 ) at Po0.05.
Association within haplotype block 1. This consisted of SNPs rs135550 and rs135549 (Figure 2 ). FBAT identified four haplotypes, of which three had frequencies of 40.01. Haplotypes 1 (T-C) and 2 (C-T) were associated with fasting LDL-C responses to fenofibrate (P ¼ 0.01 and P ¼ 0.03; Table 3 ), but were not associated with fasting TNF-a (P ¼ 0.48 and P ¼ 0.44; Table 3 ).
Association within haplotype block 2. This consisted of SNPs rs135550, rs135549, rs135543 and rs9626730 (Figure 2 ). FBAT identified 14 haplotypes, of which 7 had a frequency of 40.01. Figure 2 . Linkage disequilibrium plot for 10 single-nucleotide polymorphisms (SNPs) in the PPARa gene. Created using Haploview software. 26 PPARa, peroxisome proliferator-activated receptor alpha. Only one haplotype (show haplotype) was associated with fasting LDL-C responses to fenofibrate (P ¼ 0.02; Table 3 ), and none were associated with fasting TNF-a (all P40.05).
DISCUSSION
This study demonstrates that people who carry different PPARa variants responded differently to fenofibrate intervention with respect to reductions in LDL-C and changes in inflammation marker plasma concentrations. Although PPARa has been studied in this context before, this is the first study of its size and scope investigating these associations in a healthy population, and the first study to include the effects of PPARa variants on inflammation marker responses to fenofibrate. Fenofibrate binds to and activates PPARa. PPARs are specific transcription factors that mediate the gene regulation effects thought to induce the lipid-and inflammation-lowering effects of fibrates. We thus tested whether variants in PPARa are associated with differences in fenofibrate responses by lipids and inflammatory markers. For lipid phenotypes, two variants (rs135550 and rs135543) showed an association with change in LDL-C, both giving rise to a q-value of 0.015 after an FDR correction for multiple testing. The haplotype analysis of these two markers with a total of four markers within the haplotype block showed a significant association with LDL-C responses to fenofibrate, and raises the possibility that the true causal variant(s) is located between rs135549 and rs135543. Fibrate treatment induces the formation of larger, more buoyant LDL particles, which show an increased affinity for the LDL receptor over their smaller counterparts. 28, 29 The main mechanism of action responsible for a reduction in LDL particles is thought to be an increase in the rate of catabolism from this increased LDL receptor affinity---in hyperlipidemic patients LDL receptor-mediated uptake increased 43% after fibrate treatment, but receptor-independent catabolism remained unchanged. 28 This is the first study, to our knowledge, to report associations between the degree of change in LDL-C concentration after fenofibrate treatment and these two variants. rs135550 is in the untranslated region of the mRNA and here we report a novel association of this variant with a lipid phenotype. Variant rs135543, 2087 kb downstream of rs13550, is in the same untranslated region and has previously been associated with baseline lipids 29 and myocardial infarction as part of a threemarker haploblock. 30 Our results were confirmed with similar SNP-phenotype associations, in the expected direction, with the post-prandial data.
We did not show any variant-phenotype association with HDL-C response to fenofibrate, and although one SNP (rs4253701) showed an association with TG of Po0.05, this did not survive the correction for multiple testing (q ¼ 0.321). We are unaware of any previous associations between PPARa variants and fenofibrate response of HDL-C. Brisson et al. 31 report no association with TG response to fenofibrate and rs1800206 (commonly referred to as PPARa Leu162Val; not tested here), but Foucher et al. 32 report an association between rs4253778 and Abbreviations: FA AUC 0 --6 , fenofibric acid serum concentration area under the 0 --6 h curve; HDL-C, high-density lipoprotein cholesterol; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; SNP, single-nucleotide polymorphism; TG, triglyceride; TNF, tumor necrosis factor.
a Results from mixed linear models which controlled for age and sex, pedigree and study center. SNPs were predictors and changes in fasting triglycerides (TGs), cholesterol and inflammatory markers were outcomes. We examined PPARa variants and their effect on inflammatory marker reductions and adiponectin levels with fenofibrate treatment. No variants were associated with change in adiponectin, MCP or IL-6, although concentrations of these inflammatory markers did increase significantly in both men and women before and after the fenofibrate trial. Two previous studies reported on two of the variants used in this study (rs4253701 and rs4253728) but neither demonstrated an association between either SNP and either myocardial infarctions 34 or apoC-III levels. 35 However, these studies were seeking associations between PPARa variants and select outcomes, in contrast to our pursuits of PPARa variants as modulators of lipid or inflammatory markers in response to fenofibrate as an agonist of PPARa. We did show a significant mediation of the IL-2 increase in response to fenofibrate by the variant rs9626730 (P ¼ 0.0002; q ¼ 0.018).
Given that the increase in IL-2 was surprising, this highlights the importance of genetic variation in PPARa in protecting against this. Although there were four SNPs that showed suggested associations with TNF-a increases (Po0.05), none of these response-variant associations survived the FDR correction.
Fibrates have previously been shown to reduce a number of systemic inflammation markers such as IL-6 and TNF-a, 36 --38 presumed to act through their effects on PPARa. Other PPARs such as PPARg activation may also affect inflammation markers, but its role is more controversial and less well understood. 39 PPARa activation has been shown to interact with nuclear factorkB and activator protein-1 signaling pathways to lead to a reduction in inflammatory markers, such as IL-6. 39 It remains unclear whether this decrease is due solely to the known increase in catabolism of inflammatory markers, or because of independent effects of PPARa activation on their production. 39 Notably, reductions in IL-6 with fenofibrate have been shown to occur independently of lipid changes in patients with the metabolic syndrome, suggesting the direct effects of fenofibrate and PPARa on inflammation. 36 In our study, we show that carriers of the minor allele had reductions in IL-6, yet those homozygous for the major allele had increases in IL-6. This highlights the complexity of this biological pathway and warrants further research. Fenofibric acid is the major metabolite of fenofibrate. After oral fenofibrate administrations, fenofibrate is rapidly hydrolyzed by esterases to form fenofibric acid, the rest being excreted through urine (primary) and feces (secondary). 40 Given that serum fenofibric acid concentration has been correlated with reductions in total, and LDL-C, it is of interest to examine genotypephenotype associations with serum fenofibric acid after a standardized dose. rs135550 was significantly associated with serum fenofibric acid concentrations (P ¼ 0.024), and may be interesting given its significant association with change in LDL-C concentrations after fenofibrate treatment, however, as this variant-phenotype association did not survive the correction for multiple testing, the relationship of this variant to the lipid and inflammatory marker lowering potential of fenofibrate acid, and the role of fenofibric acid concentrations in mediating this relationship is unclear. We provide only a preliminary indication that differences in LDL-C reduction in our study, associated with rs135550 may operate through differences in systemic exposure (AUC 0À6 ) to fenofibrate acid in the serum. This relationship and others related to exposure are more likely to be elucidated with further consideration of genetic variations in the metabolic pathways of fenofibric acid's elimination.
Our analyses benefited from a strong a priori hypothesis, a good sample size for a pharmacogenetic study, and a healthy population, making generalizations to other samples less problematic than with clinical samples. However, there are some limitations: first, these associations should be tested in more racially diverse populations, and with sample sizes that allow for the stratification by gender, which was only statistically controlled for in this study. Second, it is not clear whether these SNPphenotype associations would generalize to hyperlipidemic patients, where fenofibrate treatment is targeted. Third, many of our conclusions regarding associations between a variant and both serum fenofibric acid concentrations and responses to fenofibrate did not survive the FDR correction for multiple testing, so should be considered preliminary. Third, it is not clear why some variants in high linkage disequilibrium with each other did not show the same genotype-phenotype associations. This lack of replication within our study suggests that we may have suffered from a power issue with the correction for multiple testing, and replication with a lower number of SNPs, and/or alternative phenotypes would be an important avenue of research. Finally, the finding of an increase in inflammatory markers after fenofibrate treatment was unexpected. Our data suggest that some variants are associated with the expected decrease, while others are associated with an increase in markers of inflammation. As this is the first such finding, we again heavily encourage replication in independent cohorts. Nonetheless, the SNP-phenotype associations identified in these analyses may have important implications for clinical care. Our data support results showing fenofibrate to be an effective reducer of TG, LDL-C and a modulator of inflammatory markers, and we further highlight the role of genetic variants on the PPARa gene in modulating these responses. Treating CVD, and reducing markers of CVD risk, requires complex lifestyle and pharmacologic intervention paradigms. Newer research is aimed at integrating complex genetic information into these multimodal networks of treatments to increase their efficacy. 41 The data here, which show variants in the PPARa gene modulate the response in LDL-C and IL-6 in response to fenofibrate, may be an important contributor to future paradigms that use pharmacogenetic information.
